文献类型：期刊文献

中文题名：肝复乐胶囊联合槐耳颗粒辅助治疗原发性肝癌肝动脉化疗栓塞术后临床研究

英文题名：Clinical Study on Adjuvant Therapy of Ganfule Capsules Combined with Huai'er Granules After Transcatheter Arterial Chemoembolization for Primary Liver Cancer

作者：夏家栋[1];王亮[1];何本振[1]

机构：[1]绍兴文理学院附属医院放射科,浙江绍兴312000

年份：2025

卷号：57

期号：5

起止页码：141

中文期刊名：新中医

外文期刊名：New Chinese Medicine

基金：绍兴市卫生健康科技计划项目(2023SKY082,2024SKY075);绍兴市科技局基础公益类计划项目(2024A14015);浙江省教育厅一般科研项目(Y202454875)。

语种：中文

中文关键词：原发性肝癌;肝复乐胶囊;槐耳颗粒;肝动脉化疗栓塞术;肿瘤标志物

外文关键词：Primary liver cancer;Ganfule Capsules;Huai'er Granules;Transcatheter arterial chemoembolization;Tumor markers

中文摘要：目的:观察肝复乐胶囊联合槐耳颗粒辅助治疗原发性肝癌肝动脉化疗栓塞术(TACE)后的临床疗效。方法:回顾性选择2020年1月—2023年2月在绍兴文理学院附属医院治疗的原发性肝癌患者112例,按照治疗方法不同分为对照组与观察组各56例。2组均给予TACE治疗,对照组加甲磺酸仑伐替尼胶囊治疗,观察组在对照组基础上加用肝复乐胶囊联合槐耳颗粒治疗。比较2组临床疗效、12个月生存率及不良反应发生率;比较2组治疗前后中医证候积分及血小板计数(BPC)、白蛋白(Alb)、甲胎蛋白(AFP)、异常凝血酶原(PIVKA-Ⅱ)、总胆红素(TBil)、谷草转氨酶(AST)、谷丙转氨酶(ALT)水平。结果:治疗后,2组疾病控制率比较,差异无统计学意义(P>0.05)。观察组客观有效率、12个月生存率、不良反应发生率分别为41.07%(23/56)、98.21%(55/56)、35.71%(20/56),对照组客观有效率、12个月生存率、不良反应发生率分别为23.21%(13/56)、83.93%(47/56)、55.36%(31/56),2组比较,差异均有统计学意义(P<0.05)。治疗后,2组BPC、Alb水平均较治疗前升高(P<0.05),中医证候积分及AFP、PIVKA-Ⅱ、TBil、AST、ALT水平均降低(P<0.05);观察组治疗后BPC、Alb水平高于对照组(P<0.05),中医证候积分及AFP、PIVKA-Ⅱ、TBil、AST、ALT水平低于对照组(P<0.05)。结论:肝复乐胶囊与槐耳颗粒辅助治疗原发性肝癌TACE术后疗效确切,能够改善患者肝功能,降低肿瘤标志物水平,安全性较高。

外文摘要：Objective:To observe the clinical effect of Ganfule Capsules combined with Huai'er Granules as adjuvant therapy after transcatheter arterial chemoembolization(TACE)for primary liver cancer.Methods:A retrospective analysis was conducted on 112 patients with primary liver cancer treated at the Affiliated Hospital of Shaoxing University from January 2020 to February 2023.The patients were divided into the control group and the observation group,with 56 patients in each,based on their treatment methods.Both groups received TACE for treatment.The control group was additionally treated with Lenvatinib Mesilate Capsules,while the observation group received Ganfule Capsules combined with Huai'er Granules on the basis of the control group's treatment.The clinical effects,12-month survival rate,and incidence of adverse reactions were compared between the two groups.Additionally,the scores of traditional Chinese medicine(TCM)syndromes and the levels of blood platelet count(BPC),albumin(Alb),alpha-fetoprotein(AFP),protein induced by vitamin K absence or antagonist-Ⅱ(PIVKA-Ⅱ),total bilirubin(TBil),aspartate aminotransferase(AST),and alanine aminotransferase(ALT)were compared before and after treatment.Results:After treatment,there was no statistically significant difference in disease control rate between the two groups(P>0.05).The objective response rate,12-month survival rate,and incidence of adverse reactions in the observation group were 41.07%(23/56),98.21%(55/56),and 35.71%(20/56),respectively,compared with 23.21%(13/56),83.93%(47/56),and 55.36%(31/56)in the control group,differences between the two groups being significant(P<0.05).After treatment,the BPC and Alb levels in both groups were increased when compared with those before treatment(P<0.05),while the TCM syndrome scores and the levels of AFP,PIVKA-Ⅱ,TBil,AST,and ALT were all reduced(P<0.05).The BPC and Alb levels in the observation group were higher than those in the control group after treatment(P<0.05),while the TCM syndrome scores and the levels of AFP,PIVKA-Ⅱ,TBil,AST,and ALT were lower than those in the control group(P<0.05).Conclusion:Ganfule Capsules combined with Huai'er Granules as adjuvant therapy after TACE for primary liver cancer has a definite effect,can improve liver function,reduce tumor marker levels,and has a high safety profile.